3 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Active not recruiting 1, Recruiting 1 |
Follow iptacopan: new trials by email Literature Review of iptacopan trials Research Report on iptacopan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN Iptacopan - Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase 2 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-02-21 | 2026-07-29 |
| Iptacopan in Patients With ANCA Associated Vasculitis Iptacopan, Placebo, Rituximab - Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 84 | 2024-08-05 | 2026-10-15 |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care - Lupus Nephritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 81 | 2022-08-10 | 2026-10-15 |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration Iptacopan (LNP023), Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | Novartis Pharmaceuticals | 168 | 2022-02-17 | 2026-10-27 |
| Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders Iptacopan - Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD) | Phase 2 | Terminated | Novartis Pharmaceuticals | 19 | 2021-12-21 | 2025-10-16 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria LNP023 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Novartis Pharmaceuticals | 13 | 2019-04-05 | 2024-06-18 |
| Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) iptacopan, Standard of Care - Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis | Phase 2 | Completed | Novartis Pharmaceuticals | 16 | 2018-04-09 | 2024-06-12 |
Hemoglobinuria, Paroxysmal (2) · Hemolysis (2) · Anemia, Hemolytic, Autoimmune (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Geographic Atrophy (1) · Glomerulonephritis, IGA (1) · Granulomatosis with Polyangiitis (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Macular Degeneration (1) · Microscopic Polyangiitis (1) · Proteinuria (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Vision Disorders (1) · Wet Macular Degeneration (1)
United States (5) · Germany (4) · United Kingdom (4) · Argentina (3) · China (3) · France (3) · Malaysia (3) · Spain (3) · Hungary (2) · Italy (2) · Puerto Rico (2) · Singapore (2) · South Korea (2) · Turkey (Türkiye) (2) · Australia (1)
PMID 33765419, PMID 35561315, PMID 37314061, PMID 37528520, PMID 40632630, PMID 41366634
2017 (1), 2023 (1)